A comprehensive approach to type 2 diabetes mellitus – way to reduce mortality from atherosclerosis – associated diseases

Abstract

The purpose of this review is to inform healthcare professionals that the combination of several risk factors (RF) has a serious effect on the progression of atherosclerosis, the development of cardiovascular (CV) diseases and death in people with type 2 diabetes (T2DM). Each of the factors, as a rule, enhances the effect of the other, and if the patient has several of them, then combining them with diabetes is deadly for him. Only an integrated approach to the treatment and effects on RF can improve the prognosis for patients with type 2 diabetes. It is shown that in the treatment of modern classes of hypoglycemic drugs, complex metabolic control is important. Prevention of CV disease is, therefore, a goal of treatment of T2DM as important as glycemic control. The use of drugs with proven cardiovascular benefits is recommended as part of of glucose-lowering therapy. The data of international studies of preparations of a sodium–glucose co-transporter 2 (SGLT2) inhibitor and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) various links in the pathogenesis of complications of diabetes mellitus (DM) reduce the risk of CV events. Based on the original trial results healthcare professionals should the use of antidiabetic drugs that have been proven to reduce cardiovascular events and mortality.

Keywords

• type 2 diabetes mellitus
• glycemic control
• cardiovascular risk
• atherosclerosis
• arterial hypertension
• cardiovascular composite end point
• 3p-mace